Dabigatran etexilate: Advances in anticoagulation therapy

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 771-774

  Dahl, Ola E ^a,b   Huisman, Menno V ^c  

^a Elverum Central Hospital   (Norway)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Atrial fibrillation; Dabigatran etexilate; Stroke prevention; Thromboprophylaxis; Treatment; Venous thromboembolism

Indexed keywords

DABIGATRAN ETEXILATE; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; HEART ATRIUM FIBRILLATION; HEMODYNAMIC MONITORING; HUMAN; NOTE; RECURRENT DISEASE; RISK REDUCTION; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77953516029     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.67     Document Type: Note

References (22)

1. Hawkins D. The role of oral direct thrombin inhibitors in the prophylaxis of venous thromboembolism. Pharmacotherapy 24, 179S-183S (2004).
2. Heit JA, Silverstein MD, Mohr DN et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch. Intern. Med. 159, 445-453 (1999).
3. Prandoni P, Lensing AW, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. 125, 1-7 (1996).
4. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Ann. Intern. Med. 164, 17-26 (2004).
5. Pengo V, Lensing AW, Prins MH et al.; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. 350, 2257-2264 (2004).
6. Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Ann. Intern. Med. 160, 761-768 (2000).
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983-988 (1991).
8. Gladstone DJ, Bui E, Fang J et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 40, 235-240 (2009).
9. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 454S-545S (2008).
10. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 546S-592S (2008).
11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
12. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann. Intern. Med. 120, 897-902 (1994).
13. Hylek EM, Skates SJ, Sheehan MA et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 335, 540-546 (1996).
14. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists. Chest 126(Suppl. 3), 204S-233S (2004).
15. Schulman S; Duration of Anticoagulation (DURAC) Trial Study Group. Quality of oral anticoagulant control and treatment in Sweden. J. Intern. Med. 236, 143-152 (1994). (Pubitemid 24246970)
16. Jones M, McEwan P, Morgan CL et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population. Heart 91, 472-477 (2005).
17. Fiessinger J-N, Huisman MV, Davidson BL et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 293, 681-689 (2005).
18. Olsson SB; Executive Committee of the SPORTIF III Investigators. Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-valvular Atrial Fibrillation (SPORTIF III): randomized controlled trial. Lancet 362, 1691-1698 (2003).
19. Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293, 690-698 (2005).
20. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342-2352 (2009).
21. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2009).
22. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Ann. Intern. Med. 131, 927-934 (1999).